Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III-study for Evaluation of Induction Therapy Before Stem Cell Mobilization and Tandem High-dose Melphalan in Multiple Myeloma Patients 60 to 70 Years of Age

NCT02288741 is registered in ClinicalTrials.gov with WiSP Wissenschaftlicher Service Pharma GmbH as lead sponsor.

NCT NCT02288741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02288741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III-study for Evaluation of Induction Therapy Before Stem Cell Mobilization and Tandem High-dose Melphalan in Multiple Myeloma Patients 60 to 70 Years of Age
Lead sponsor
WiSP Wissenschaftlicher Service Pharma GmbH
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2001
Completion date
September 30, 2012
Enrollment
549 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma